Literature DB >> 25015643

A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling.

Ling Lin1, Lynn Chamberlain1, Magnolia L Pak1, Arvindhan Nagarajan2, Romi Gupta2, Lihua J Zhu3, Casey M Wright4, Kwun M Fong5, Narendra Wajapeyee2, Michael R Green6.   

Abstract

UNLABELLED: To discover new tumor-suppressor genes (TSG), we developed a functional genomics approach in which immortalized but nontumorigenic cells were stably transduced with large-scale shRNA pools and tested for tumor formation in mice. Identification of shRNAs in resulting tumors revealed candidate TSGs, which were validated experimentally and by analyzing expression in human tumor samples. Using this approach, we identified 24 TSGs that were significantly downregulated in human lung squamous cell carcinomas (hLSCC). Amplification of fibroblast growth factor receptor 1 (FGFR1), which aberrantly increases FGFR signaling, is a common genetic alteration in hLSCCs. Remarkably, we found that 17 of the TSGs encode repressors of FGFR signaling. Knockdown of 14 of these TSGs transformed immortalized human bronchial epithelial cells and, in most cases, rendered them sensitive to FGFR inhibitors. Our results indicate that increased FGFR signaling promotes tumorigenesis in many hLSCCs that lack FGFR1 amplification or activating mutations. SIGNIFICANCE: A functional genomics approach identifies new lung TSGs whose loss aberrantly increases FGFR signaling to promote tumorigenesis. These TSGs are frequently downregulated in hLSCCs, indicating that increased FGFR signaling promotes tumorigenesis in many hLSCCs lacking FGFR1 amplification or activating mutations. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25015643      PMCID: PMC4184919          DOI: 10.1158/2159-8290.CD-13-0747

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  45 in total

1.  Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells.

Authors:  Lili Zhang; Xiaoyu Pan; John W B Hershey
Journal:  J Biol Chem       Date:  2006-12-14       Impact factor: 5.157

Review 2.  Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.

Authors:  Puja Gaur; Diane R Bielenberg; Shaija Samuel; Debashish Bose; Yunfei Zhou; Michael J Gray; Nikolaos A Dallas; Fan Fan; Ling Xia; Jia Lu; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

Review 3.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

Review 4.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

Authors:  Maria Vittoria Dieci; Monica Arnedos; Fabrice Andre; Jean Charles Soria
Journal:  Cancer Discov       Date:  2013-02-15       Impact factor: 39.397

5.  Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK.

Authors:  T McKinnon; C Chakraborty; L M Gleeson; P Chidiac; P K Lala
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

6.  Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

Authors:  Joseph M Gozgit; Matthew J Wong; Lauren Moran; Scott Wardwell; Qurish K Mohemmad; Narayana I Narasimhan; William C Shakespeare; Frank Wang; Tim Clackson; Victor M Rivera
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

7.  FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

Authors:  Vito Guagnano; Audrey Kauffmann; Simon Wöhrle; Christelle Stamm; Moriko Ito; Louise Barys; Astrid Pornon; Yao Yao; Fang Li; Yun Zhang; Zhi Chen; Christopher J Wilson; Vincent Bordas; Mickaël Le Douget; L Alex Gaither; Jason Borawski; John E Monahan; Kavitha Venkatesan; Thomas Brümmendorf; David M Thomas; Carlos Garcia-Echeverria; Francesco Hofmann; William R Sellers; Diana Graus-Porta
Journal:  Cancer Discov       Date:  2012-09-20       Impact factor: 39.397

8.  Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.

Authors:  Steven G Gray; Nael Al-Sarraf; Anne-Marie Baird; Mary-Clare Cathcart; Eilish McGovern; Kenneth J O'Byrne
Journal:  Eur J Cancer       Date:  2009-10-07       Impact factor: 9.162

9.  Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.

Authors:  H Kouhara; S Kurebayashi; K Hashimoto; S Kasayama; M Koga; T Kishimoto; B Sato
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

10.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

View more
  8 in total

1.  In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Authors:  Eleanor R C Fiedler; Arjun Bhutkar; Emily Lawler; Rana Besada; Michael T Hemann
Journal:  Blood Adv       Date:  2018-06-12

2.  KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity.

Authors:  Romi Gupta; Parmanand Malvi; Keshab Raj Parajuli; Radoslav Janostiak; Suresh Bugide; Guoping Cai; Lihua Julie Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

3.  Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.

Authors:  Tomohiko Kakumu; Mitsuo Sato; Daiki Goto; Toshio Kato; Naoyuki Yogo; Tetsunari Hase; Masahiro Morise; Takayuki Fukui; Kohei Yokoi; Yoshitaka Sekido; Luc Girard; John D Minna; Lauren A Byers; John V Heymach; Kevin R Coombes; Masashi Kondo; Yoshinori Hasegawa
Journal:  Cancer Sci       Date:  2017-04-25       Impact factor: 6.716

4.  Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.

Authors:  Shu Feng; Longjiang Shao; Patricia Castro; Ilsa Coleman; Peter S Nelson; Paul D Smith; Barry R Davies; Michael Ittmann
Journal:  Oncotarget       Date:  2017-01-24

Review 5.  [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].

Authors:  Ming Dong; Tong Li; Jun Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20

6.  Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.

Authors:  R Gupta; Q Yang; S K Dogra; N Wajapeyee
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

7.  Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression.

Authors:  Parmanand Malvi; Radoslav Janostiak; Arvindhan Nagarajan; Guoping Cai; Narendra Wajapeyee
Journal:  PLoS Genet       Date:  2019-10-07       Impact factor: 5.917

8.  Knockdown of DEAD-box RNA helicase 52 (DDX52) suppresses the proliferation of melanoma cells in vitro and of nude mouse xenografts by targeting c-Myc.

Authors:  Qiang Wang; Leqi Qian; Mengyuan Tao; Jiaqi Liu; Fa-Zhi Qi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.